Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...

Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...

Merck & Co.’ Inc.’s stock MRK rose 2% premarket Tuesday, after the company reported positive results for a new formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck said a ...

Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

The ongoing trial is assessing the drug's performance both as a standalone therapy and in combination with the programmed cell death protein 1 (PD-1) checkpoint inhibitor Keytruda. It is structured as ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...

Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...

Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion, recommending the approval of its ...

At age 20, while studying sports management and marketing in college, Sean Kukoleck's life was disrupted by cancer. He suffered his first-ever seizure, leading to the discovery of a large mass on ...

Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...

The U.S. Food and Drug Administration approved the Keytruda combination in malignant pleural mesothelioma in September. Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...